Market Trends of Tourette Syndrome Treatment Industry
The Antipsychotics Segment is Expected to Witness Significant Growth During the Forecast Period
Antipsychotic drugs are expected to hold a significant market share due to their ability to treat tics to a greater extent than non-antipsychotic drugs. Antipsychotic drugs were developed for treating schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine, specifically by blocking dopamine receptors, mainly the D2 receptor. Thus, such a robust therapeutic effect of antipsychotics is one of the significant factors driving the segment's growth during the forecast period.
The increasing use of antipsychotic drugs and their efficacy in treating Tourette syndrome is one of the major factors driving the segment's growth during the forecast period. For instance, as per the study published by Cureus Journal in February 2022, antipsychotic drugs have been commonly used as a treatment for Tourette syndrome since Food and Drug Administration approval. Haloperidol and pimozide have been used for a long time and have shown significant efficacy. Haloperidol can cause a 91.0% reduction in the severity of tics when given at the maximum dose. Therefore, such instances indicating the high effectiveness of antipsychotic drugs in treating the Tourette syndrome segment are projected to drive the segment's growth during the forecast period.
Furthermore, the rising number of clinical trials testing the efficacy of antipsychotic drugs for treating TS disease is also projected to drive segment growth during the forecast period. For instance, in March 2023, Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for treating Tourette Syndrome.
Therefore, the high efficacy of antipsychotic drugs in treating TS and the rising number of clinical trials are projected to drive the segment's growth during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to register a significant share in the Tourette syndrome treatment market owing to the increasing prevalence of Tourette syndrome, growing awareness, and strategic initiatives taken by the market players, such as research and clinical development.
The growth is due to factors such as the increasing prevalence of Tourette syndrome and increasing research related to the syndrome in this region. For instance, as per the report published by Tourette Canada in January 2022, Tourette syndrome affects approximately 1.0% of the population. However, some recent studies suggest that the prevalence rate may be as high as 3.8%. Tics are quite common in childhood, with studies showing that 24.0% of children may develop simple tics. Therefore, such instances indicate that the demand for Tourette syndrome treatment may increase, propelling the market's growth for treatments.
Furthermore, several regional awareness campaigns to educate people on diseases and treatment plans are anticipated to boost the market's growth during the forecast period. For instance, the Tourette Association of America celebrates Tourette Syndrome Awareness Month from May 15 to June 15 every year to increase awareness about the syndrome among people. Thus, such instances are anticipated to drive the market's growth in the country.
Key product launches, high concentration of market players or manufacturer's presence, acquisitions and partnerships among major players, and public and private initiatives toward Tourette syndrome in the United States are some of the factors driving the growth of the Tourette syndrome treatment market in the country. For instance, in April 2023, Camber Pharmaceuticals expanded its product line by introducing Aripiprazole Oral Solution, enhancing its existing range that already features Aripiprazole Tablets, primarily utilized in treating Tourette's disorder.
Therefore, owing to the aforementioned factors, the market's growth is anticipated to grow in North America.
